Abstract:Large-scale pharmacogenomic screens of cancer cell lines have emerged as an attractive pre-clinical system for identifying tumor genetic subtypes with selective sensitivity to targeted therapeutic strategies. Application of modern machine learning approaches to pharmacogenomic datasets have demonstrated the ability to infer genomic predictors of compound sensitivity. Such modeling approaches entail many analytical design choices; however, a systematic study evaluating the relative performance attributable to each design choice is not yet available. In this work, we evaluated over 110,000 different models, based on a multifactorial experimental design testing systematic combinations of modeling factors within several categories of modeling choices, including: type of algorithm, type of molecular feature data, compound being predicted, method of summarizing compound sensitivity values, and whether predictions are based on discretized or continuous response values. Our results suggest that model input data (type of molecular features and choice of compound) are the primary factors explaining model performance, followed by choice of algorithm. Our results also provide a statistically principled set of recommended modeling guidelines, including: using elastic net or ridge regression with input features from all genomic profiling platforms, most importantly, gene expression features, to predict continuous-valued sensitivity scores summarized using the area under the dose response curve, with pathway targeted compounds most likely to yield the most accurate predictors. In addition, our study provides a publicly available resource of all modeling results, an open source code base, and experimental design for researchers throughout the community to build on our results and assess novel methodologies or applications in related predictive modeling problems.

Drug Response Modeling across Cancers: Proteomics vs. Transcriptomics

A Proteomic Landscape of Pharmacologic Perturbations for Functional Relevance

Efficient parameterization of large-scale mechanistic models enables drug response prediction for cancer cell lines

SYSTEMATIC ASSESSMENT OF ANALYTICAL METHODS FOR DRUG SENSITIVITY PREDICTION FROM CANCER CELL LINE DATA

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification

Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines

Dose-response modeling in high-throughput cancer drug screenings: An end-to-end approach

Evaluating the Molecule-Based Prediction of Clinical Drug Responses in Cancer.

DROEG: a method for cancer drug response prediction based on omics and essential genes integration

Precision and recall oncology: combining multiple gene mutations for improved identification of drug-sensitive tumours

Deep learning and multi-omics approach to predict drug responses in cancer

The prognostic genes model of breast cancer drug resistance based on single-cell sequencing analysis and transcriptome analysis

Omics and Computational Modeling Approaches for the Effective Treatment of Drug-Resistant Cancer Cells

TransCell: In silico Characterization of Genomic Landscape and Cellular Responses by Deep Transfer Learning

Model ensembling as a tool to form interpretable multi-omic predictors of cancer pharmacosensitivity

An Innovative Multi-Omics Model Integrating Latent Alignment and Attention Mechanism for Drug Response Prediction

Proteogenomic Integration Reveals Therapeutic Targets in Breast Cancer Xenografts.

Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation

Modeling Expression Plasticity of Genes That Differentiate Drug-Sensitive from Drug-Resistant Cells to Chemotherapeutic Treatment